Normal imaging findings after aortic valve implantation on 18F-Fluorodeoxyglucose positron emission tomography with computed tomography by Wahadat, A.R. (Ali R.) et al.
ORIGINAL ARTICLE
Normal imaging findings after aortic valve
implantation on 18F-Fluorodeoxyglucose
positron emission tomography with computed
tomography
Ali R. Wahadat, MD,a,b,c,i Wilco Tanis, MD, PhD,c
Asbjørn M. Scholtens, MD,d,f Margreet Bekker, MD,e Laura H. Graven, MD,a
Laurens E. Swart, MD, PhD,a,b Annemarie M. den Harder, MD, PhD,f
Marnix G. E. H. Lam, MD, PhD,f Linda M. de Heer, MD, PhD,g,h
Jolien W. Roos-Hesselink, MD, PhD,b and Ricardo P. J. Budde, MD, PhDa,b
a Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The
Netherlands
b Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The
Netherlands
c Department of Cardiology, Haga Teaching Hospital, The Hague, The Netherlands
d Department of Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands
e Department of Thoracic Surgery, Thoraxcenter, Erasmus Medical Center, Rotterdam, The
Netherlands
f Department of Radiology and Nuclear Medicine, Utrecht Medical Center, Utrecht, The
Netherlands
g Department of Cardiothoracic Surgery, Utrecht Medical Center, Utrecht, The Netherlands
h Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, The
Netherlands
i Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
Received Nov 12, 2019; accepted Dec 17, 2019
doi:10.1007/s12350-019-02025-y
Background. To determine the normal perivalvular 18F-Fluorodeoxyglucose (18F-FDG)
uptake on positron emission tomography (PET) with computed tomography (CT) within one
year after aortic prosthetic heart valve (PHV) implantation.
Methods. Patients with uncomplicated aortic PHV implantation were prospectively
included and underwent 18F-FDG PET/CT at either 5 (± 1) weeks (group 1), 12 (± 2) weeks
(group 2) or 52 (± 8) weeks (group 3) after implantation. 18F-FDG uptake around the PHV was
scored qualitatively (none/low/intermediate/high) and quantitatively by measuring the maxi-
mum Standardized Uptake Value (SUVmax) and target to background ratio (SUVratio).
Results. In total, 37 patients (group 1: n = 12, group 2: n = 12, group 3: n = 13) (mean age
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66 ± 8 years) were prospectively included. Perivalvular 18F-FDG uptake was low (8/12 (67%))
and intermediate (4/12 (33%)) in group 1, low (7/12 (58%)) and intermediate (5/12 (42%)) in
group 2, and low (8/13 (62%)) and intermediate (5/13 (38%)) in group 3 (P = 0.91). SUVmax was
4.1 ± 0.7, 4.6 ± 0.9 and 3.8 ± 0.7 (mean ± SD, P = 0.08), and SUVratio was 2.0 [1.9 to 2.2], 2.0
[1.8 to 2.6], and 1.9 [1.7 to 2.0] (median [IQR], P = 0.81) for groups 1, 2, and 3, respectively.
Conclusion. Non-infected aortic PHV have similar low to intermediate perivalvular 18F-
FDG uptake with similar SUVmax and SUVratio at 5, 12, and 52 weeks after implantation. (J
Nucl Cardiol 2020)
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Abbreviations
PHV Prosthetic heart valve
18F-FDG 18F-Fluorodeoxyglucose
PET Positron emission tomography
ESC European Society of Cardiology
QVSH Qualification visual score for
hypermetabolism
EARL European Association of Nuclear Med-
icine Research Ltd
TTE Transthoracic echocardiography
TEE Transesophageal echocardiography
INTRODUCTION
Diagnosing prosthetic heart valve (PHV) endocardi-
tis remains difficult.1,2 18F-Fluorodeoxyglucose (18F-
FDG) Positron Emission Tomography (PET) with com-
puted tomography (CT) was added as an additional
diagnostic tool in the 2015 European Society of Cardi-
ology (ESC) guidelines for infectious endocarditis.2
Since then, 18F-FDG PET/CT has shown great potential
for diagnosing PHV endocarditis, with a good sensitivity
and specificity.3–5 For accurate interpretation of 18F-
FDG PET/CT scans in PHV patients suspected for
endocarditis, knowing the normal amount and pattern of
18F-FDG uptake around PHV’s (due to the normal tissue
healing response) is important. The ESC guidelines
suggest using 18F-FDG PET/CT only if the PHV was
implanted[ 3 months prior to the scan because it was
assumed that the normal healing response after aortic
PHV implantation and its associated 18F-FDG uptake
would cause false positive results and misinterpretations
within this time window.2 However, this arbitrary time
period is not based on any evidence and has recently
been questioned in other studies.3,6 Indications of the
normal 18F-FDG uptake patterns and cut-off values for
abnormal uptake have been obtained from retrospective
assessment of a limited number of patients with a PHV
who underwent 18F-FDG PET/CT for indications other
than suspected endocarditis.3,7 Recently, the first
prospective study regarding baseline assessment of
normal 18F-FDG uptake patterns around PHV’s was
published showing no significant differences between
18F-FDG uptake around PHV’s at 1, 6 and 12 months
after surgery.8 In this study, we prospectively assessed
the qualitative and quantitative baseline perivalvular
18F-FDG uptake at three different time points within the
first year following aortic PHV implantation, in order to
obtain normal 18F-FDG uptake reference values.
MATERIALS AND METHODS
Patient Selection and Classification
In this prospective multi-center cross-sectional study, we
included patients (age C 50 years) from two different hospitals
in the Netherlands (Erasmus Medical Center, Rotterdam, and
the University Medical Center, Utrecht) who had undergone an
uncomplicated aortic PHV implantation. An uncomplicated
PHV implantation was defined as a PHV implantation without
any surgical complication during or after the operation as well
as the absence of signs of infection as mentioned in the
surgical reports and the electronic patient files. The inclusion
and exclusion criteria are detailed in Table 1. The medical
ethics committee approved the study (NL42743.041.12). All
patients provided written informed consent.
Patients were divided into three groups and received an
18F-FDG PET/CT at either 5 (± 1) weeks (group 1), 12 (± 2)
weeks (group 2), or 52 (± 8) weeks (group 3) following valve
implantation. The assignment of patients to each group
depended on logistic factors such as availability of time slots
on the PET/CT scanner and patient availability of one of the
three time intervals after surgery.
Included patients had undergone uncomplicated valve
implantations and did not have any clinical signs of prosthetic
valve infection (fever, shivers, dyspnea, etc) at the time of the
18F-FDG PET/CT.
Image Acquisition
18F-FDG PET/CT To induce free fatty acid metabo-
lism and suppress myocardial glucose metabolism, patients
followed a 24-hour low carbohydrate diet, of which the last 12
hours were spent fasting.9–11 Thereafter, patients received an
intravenous 18F-FDG injection of 2.0 MBq/kg. Patients were
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hydrated with 1000 ml of water 1 hour prior to image
acquisition. Blood glucose levels were checked before 18F-
FDG injection and the limit was set to 8.9 mmol/L. Approx-
imately 1 hour after 18F-FDG injection, the PET/CT was
performed using a Biography Sensation 16scanner (SIEMENS
Medical, Germany). Before the PET acquisition, a low dose
CT scan was performed for attenuation correction. A PET-scan
of the heart was then obtained with 3-minute acquisitions per
bed position using a 3-dimensional acquisition mode. Atten-
uation-corrected PET images were reconstructed with an
ordered-subset expectation-maximization iterative reconstruc-
tion algorithm.
Image Analysis and Interpretation
18F-FDG PET/CT analysis Uptake of 18F-FDG
around the PHV was scored both qualitatively and quantita-
tively by an experienced nuclear medicine physician. For
qualitative analyses, the Qualification Visual Score for Hyper-
metabolism (QVSH) was used, scoring the uptake as ‘‘none’’
(no or less than mediastinal uptake), ‘‘low’’ (more than
mediastinal uptake but less than in the liver), ‘‘intermediate’’
(more than liver uptake), or ‘‘high’’ (intense uptake). Medi-
astinal uptake was defined as the mean uptake in the blood
pool of the descending aorta at the level of the left atrium.
Additionally, the location (former left coronary cusp (LCC)/
right coronary cusp (RCC)/non coronary cusp (NCC), circular,
PHV struts only or ascending aorta) of this uptake was
specified. Quantitative analyses were performed by measuring
the maximum Standardized Uptake Value (SUVmax) and target
to background ratio (SUVratio) on standardized European
Association of Nuclear Medicine Research Ltd. (EARL) and
non-EARL reconstructions using commercially available soft-
ware (OsiriX MD version 7.5, Switzerland). SUVmax was
measured in an automated volume of interest (VOI) around the
PHV, which was visually verified to include the whole valve
region. The SUVratio was then calculated as the ratio of the
SUVmax and the mean SUV in the blood pool of the
descending aorta, taking care not to include the vessel wall.
Myocardial suppression was scored as ‘‘fully sup-
pressed’’ (no uptake), ‘‘low’’ (more than mediastinal uptake
but less than in the liver), ‘‘intermediate’’ (more than liver
uptake), ‘‘high focal’’ (much more than liver uptake, but
focal), ‘‘high diffuse’’ (much more than liver uptake, diffuse).
Statistics Descriptive statistics were used for analysis
of the outcomes. For continuous variables, means and standard
deviations (SD) were used in case of normal distribution. In
case of non-normal distribution, medians and interquartile
ranges (IQR) were used. The IQR and confidence interval (CI)
were denoted in square brackets. Comparisons between groups
were made using the Chi-square test for categorical variables.
For continuous variables One-way Analysis of Variance
(ANOVA) was used in case of normal distribution and Kruskal
Wallis test in case of non-normal distribution. A significance
level of P = 0.05 and 95% confidence intervals (CI) were used.
RESULTS
Patients Characteristics and Classification
A total of 38 patients were initially included after
signing written informed consent. One patient was
excluded after failure to undergo the PET/CT scan due
to scanner malfunction. Age (mean ± SD) of the 37
patients finally included in this study was 66 ± 8 years
(group 1: 65 ± 7; group 2: 66 ± 8; group 3: 67 ± 10;
P = 0.87) and most of the patients were male (n = 24,
65%) (group 1: n = 8; group 2: n = 10; group 3: n = 6;
P = 0.15). There were 25 (68%) biological and 12
(32%) mechanical prosthetic valves, equally distributed
between groups (P = 0.99). Surgical adhesives such as
BioGlue that are known to be FDG-avid, were not used
during any of the implantations. No patient was
suspected of having endocarditis prior to the PET/CT
scan. Patients were included in either group 1 (n = 12),
group 2 (n = 12), or group 3 (n = 13). Due to logistic
problems, 8 patients (group 1: n = 2; group 2 n = 3;
group 3: n = 3) underwent the scan outside the time
interval originally set-out for each group. The 2 patients
in group 1 were scanned 2 and 5 days later than the
maximum adjusted days (5 ± 1 week) for group 1. The 3
patients in group 2 were scanned 15, 22, and 38 days
later and the 3 patients in group 3 were scanned 15, 23,
and 36 days later than originally planned. Baseline
characteristics for the overall population and the three
groups are summarized in Table 2.
18F-FDG PET/CT Findings
The median time between PHV implantation and
18F-FDG PET/CT was 37 [IQR 35–42], 93 [IQR 87 to
109], and 370 [IQR 356 to 430] days for group 1, 2, and
3 respectively (P\ 0.01). Median 18F-FDG dosage was
166 [IQR 145 to 183] MBq and not significantly
different between the groups (P = 0.16). Preparation
according to carbohydrate diet protocol was followed by
36/37 (97%) patients. Three patients had fasted less than
12 hours prior to the scan, 1 patient failed to follow the
low carbohydrate diet and 1 patient inadvertently
received a double amount of 18F-FDG activity. Myocar-
dial 18F-FDG uptake was scored as ‘‘fully suppressed’’
in 18/37 (49%) and as intermediate or less in 29/37
(78%) patients. One patient was scored as focal high and
7 patients as diffuse high myocardial uptake. The
interpretation of one scan was hampered due to the
diffuse high myocardial FDG uptake.
The QVSH around the PHV was scored as follows
for group 1: low in 8/12 (67%) and intermediate in 4/12
(33%) patients; group 2: 7/12 (58%) low and 5/12 (42%)
intermediate and for group 3: 8/13 (62%) low and 5/13
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(38%) intermediate. Comparison between groups
showed no significant difference in QVSH (P = 0.91).
The distribution of 18F-FDG uptake was circular in most
cases (78%) and not significantly different between the 3
groups (P = 0.50). The 18F-FDG uptake around the
PHVs on a reconstructed view in the PHV plane of
attenuation-corrected images, non-attenuation-corrected
and fused attenuation-corrected images with CT of all
patients is shown in Figure 1.
Quantitative analyses on the non-EARL attenua-
tion-corrected images showed a SUVmax of 4.1 ± 0.8
(mean ± SD) and a median[IQR] SUVratio of 2.0 [1.8 to
2.2] for all included patients. The SUVmax around the
PHV was 4.1 ± 0.7, 4.6 ± 0.9, and 3.8 ± 0.7 (mean ±
SD) in group 1, 2, and 3 respectively, with no
significant difference between the 3 groups (p = 0.08).
The median[IQR] SUVratio around the PHV was 2.0 [1.9
to 2.2], 2.0 [1.8 to 2.6], and 1.9 [1.7 to 2.0] with no
significant difference between the three groups
(P = 0.81) (Table 3). Quantitative analyses on the
EARL reconstruction images showed an average SUV-
max and SUVratio of 3.6 ± 0.5 and 1.8 ± 0.3
(mean ± SD), respectively. SUVmax around the PHV
was 3.6 ± 0.5, 3.8 ± 0.5 and 3.3 ± 0.6 (mean ± SD) in
group 1, 2 and 3 respectively, with no significant
difference between the 3 groups (P = 0.14). Likewise,
the SUVratio around the PHV was 1.8 ± 0.2, 1.8 ± 0.3,
and 1.7 ± 0.3(mean ± SD) with no significant difference
between the three groups either (P = 0.41). The mini-
mum and maximum measured SUVratio in the study
population was 1.4 and 2.5, respectively. EARL SUVra-
tio was\ 2.3 in 97% and\ 2.1 in 92% of the cases. The
distribution of non-EARL and EARL SUVmax and
SUVratio are demonstrated in Figure 2.
Elevated 18F-FDG uptake elsewhere in the body
was seen in 21/37 (57%) of patients and was not
significantly different between the 3 groups
(P = 0.18). This elevated 18F-FDG uptake was mainly
Table 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age C 50 years
Patients after uncomplicated PHV implantation in aortic
position (mechanical and biological PHVs)
Normal routine follow up TTE (standardly performed 5
days after operation) or intra-operative TEE. With no
signs of obstruction, endocarditis or significant
paravalvular leakages
Weight\110 kg
Known contrast allergy
Known renal impairment (according to local hospital
guidelines)
Diabetes Mellitus
Mild contractile dysfunction of the left and/or right
ventricle (Eyeballing, Ejection fraction\45 %, TAPSE
\14 mm)
Active cardiac decompensation
Uncontrolled cardiac arrhythmias
Suspicion of active endocarditis
Previous participation in scientific studies using
radiation
(Possible) pregnancy in pre-menopausal women above
50 years not on reliable birth control therapy. Other
contraindications for contrast use according to the
standard daily clinical routine according to the
protocol by the department of radiology
Use of pericardial patches and re-operation of aortic
PHV in past medical history
Contraindication for Computed Tomography
Angiography according the standard daily clinical
routine
Refusal to be informed about potential additional CT or
FDG PET findings
If already included in group 1, patients cannot be
included in group 2 or 3
PHV, prosthetic heart valve; TTE, transthoracic echocardiogram; TEE, transesophageal echocardiogram; TAPSE, tricuspid annular
plane systolic excursion; CT, computed tomography; FDG PET, fluorodeoxyglucose positron emission tomography
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seen in the thoracic lymphnodes 9/21 (38%) and
considered physiological. Other areas of elevated uptake
consisted of costal fractures 3/21 (14%), pleural uptake
(possible pulmonary nodule) 2/21 (10%), acromioclav-
icular joint (due to degeneration) 2/21 (10%), thyroid
(possible hyperthyroidism) 1/21 (5%), arytenoid (phys-
iological) 1/21 (5%), possible pathological oesophageal
uptake 2/21 (10%), diffuse in muscles 1/21 (5%), and
focal uptake due to a surgical clip.
DISCUSSION
The present study shows that patients with non-
infected aortic PHV have similar low to intermediate
mostly circular 18F-FDG uptake around the PHV at 5, 12
and 52 weeks after implantation and a mean ± SD
SUVmax of 4.1 ± 0.8 and a median[IQR] SUVratio of
2.0[1.8 to 2.2].
Nowadays, 18F-FDG PET/CT is an important diag-
nostic method in suspected PHV endocarditis, especially
in cases where the diagnosis cannot be confirmed with
transthoracic (TTE) or transesophageal echocardiogra-
phy (TEE). However, in patients with a recent PHV
implantation (\ 3 months), the use of 18F-FDG PET/CT
is not advised due to possible false positive findings
caused by post-surgical inflammation.2 Misinterpreta-
tion of 18F-FDG PET/CT findings could have major
inappropriate therapeutic consequences. Patients may be
treated while this is not necessary and counterwise not
be treated while this is obligatory. Therefore, caution
with the interpretation of 18F-FDG PET/CT in the early
weeks after PHV implantation is advised, especially in
cases of complicated surgery. In such cases, the inflam-
mation response due to the complications could be
severe and cause non-diagnostic or false positive 18F-
FDG PET/CT results. It is therefore crucial to be able to
recognize normal 18F-FDG distribution patterns and
establish a quantitative cut-off value for pathological
18F-FDG uptake around the PHV.
Quantitative measurements of 18F-FDG uptake
around the PHV in our study demonstrated a media-
n[IQR] SUVratio of 2.0 [1.9 to 2.2] for patients at 5
weeks after surgery, with no statistically significant
difference compared to 3 months and 1 year (2.0 [1.8 to
2.6] and 1.9 [1.7 to 2.0], respectively; P = 0.81). These
results corroborate the scarce known literature about this
matter. Mathieu et al.7 reported on a retrospectively
included group of 35 patients with aortic PHVs who
underwent a PET/CT scan\ 3 months and[ 3 months
after PHV implantion for either oncological imaging,
large vessel vasculitis or suspicion of prosthetic valve
endocarditis that was subsequently rejected, and found a
median SUVmax of 3.6 [2.1 to 8.0, range] and a median
SUVratio of 1.9 [1.3 to 6.6, range] on non-EARLT
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attenuation-corrected images. No significant difference
in SUVmax and SUVratio between the PHVs implanted
\ 3 months and those that were implanted[ 3 months
prior to the PET/CT scan was found.7 However, these
results should be interpreted with some caution because:
(1) the patient population was diverse and included
patients with vasculitis and a rejected suspicion of
endocarditis and (2) 24/35 (69%) of the valves were
implanted more than 1 year ago. The authors also
reported a much higher median SUVmax of 4.7 and
SUVratio of 2.7 in the patients with vasculitis compared
to the other groups.7 Roque et al.8 have recently
presented a prospective analysis of 18F-FDG uptake at
3 different time points in the first year after PHV
implantation. The study method had similarities with our
study, but there were some differences. Roque et al.
included also patients post mitral valve implantation,
and each patient received 3 times a PET/CT scan in the
time periods of 1, 6, and 12 months after valve
implantation. Despite these differences, their results
also showed no significant difference in 18F-FDG uptake
between scans made in the three different time periods
and their conclusion that the three months safety period
should be reconsidered is in line with our conclusion.
Recently, in a retrospectively collected cohort of
243 patients, we found that the optimal diagnostic cut-
off value to diagnose PHV endocarditis for the EARL-
standardized SUVratio was[ 2.0.
3 In our current study
the maximum measured EARL SUVratio was 2.5 and
97% of scans had an EARL SUVratio of less than 2.3,
indicating that the cut-off value might be slightly higher
than the[ 2.0 reported earlier by Swart et al. in the first
year after PHV implantation3 and also higher than the
mean values reported by Mathieu et al.7
In our current study, we found only diffuse 18F-
FDG uptake around the PHV with mostly a circular
pattern (29/37, 78%) and without focal enhancement.
The distribution of 18F-FDG can differ widely and its
definition is still unclear; however, some of the uptake
patterns (eg. diffuse around PHV without focal enhance-
ment) have been associated with physiological uptake
after PHV implantation.7 Furthermore, physiological
myocardial uptake during 18F-FDG PET/CT can mask
adjacent abnormal 18F-FDG uptake around the PHV.
Therefore a preparatory low carbohydrate diet that may
be supplemented by an intravenous injection of heparin
is necessary for reducing myocardial 18F-FDG uptake in
order to avoid false positive 18F-FDG PET/CT
results.9–12 In our study, one patient had failed to follow
the prepatory low carbohydrate diet and demonstrated
indeed a high level of myocardial 18F-FDG uptake
Figure 1. 18F-FDG uptake around the PHV on reconstructed views in plane with the PHV of
attenuation-corrected (AC) images, non-attenuation-corrected (NAC) and fused attenuation-
corrected images with CT in all patients. Scaling was set the same for all AC images (0-7MBq).
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making correct measurement of the SUV values more
difficult (Figure 3).
Our study has some limitations. Eight patients
(group 1: n = 2, group 2: n = 3, and group 3: n = 3)
received the scan somewhat later than the time frame
adjusted for each group. This was due to logistic
reasons. Another limitation of this study was that the
scan was performed once in every patient and not
multiple times in the same patient to actually see a
change over time in the uptake patterns and SUV values.
This approach was not deemed feasible due to the high
radiation dose of multiple PET/CT scans in individual
healthy patients this would imply. Furthermore, our
study population only included patients with an aortic
prosthetic valve, and hence we cannot draw any con-
clusion regarding normal 18F-FDG findings for
prosthetic valve in other locations or regarding com-
bined aortic valve and ascending aorta replacements
(e.g., Bentall procedure). Excluding obese patients and
patients with diabetes mellitus could also be seen as a
limitation to the applicability of our results. Both
conditions can affect the healing process following
surgery and could therefore potentially impact 18F-FDG
uptake. However, in order to prevent inadequate glucose
levels prior to the PET and restrict the radiation
exposure to patients, the exclusion of these patients
was necessary. In total 51% of the patients did not have
fully suppressed myocardium and this could be seen as a
potential confounder to the qualitative and quantitative
18F-FDG measurements.
Although the measurements done by the nuclear
medicine physicians were carefully done not to include
myocardial uptake, this could not always have been
prevented. Thus, this could be seen as a limitation of our
study.
In conclusion, non-infected aortic PHV have similar
low to intermediate mostly circular perivalvular 18F-
FDG uptake at 5, 12, and 52 weeks after implantation
and an average SUVmax of 4.1 ± 0.8 and a median[IQR]
SUVratio of 2.0 [1.8 to 2.2]. These normal
18F-FDG
uptake values and patterns provide further evidence that
18F-FDG PET-CT can be used as a diagnostic tool for
the detection of endocarditis even shortly after aortic
PHV implantation and the recommendation to not
perform PET-CT within the first three months after
PHV implantation in the 2015 ESC guidelines for the
management of infective endocarditis should be
reconsidered.
Figure 2. Boxplots of the non-EARL (A, B) and EARL (C,D) SUVmax and SUVratio measurement
distribution in each group. The dots indicated as ‘‘15’’, ‘‘18’’, ‘‘21’’, ‘‘27’’ (A) ‘‘9’’, ‘‘15’’, ‘‘36’’
(B) ‘‘27’’ and ‘‘36’’ (C) are outliers in the SUVmax and SUVratio measurements.
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NEW KNOWLEDGE GAINED
Our study supports previous observations on the
normal perivalvular 18F-FDG uptake within the first year
after PHV implantation and showed no significant
difference in 18F-FDG uptake at 5 weeks, 12 weeks, or
52 weeks after implantation. These findings may help
clinicians to differentiate between normal and patholog-
ical perivalvular 18F-FDG uptake and suggest the use of
18F-FDG PET/CT as an extra imaging tool in the
diagnostic workup of patients with recent aortic PHV
implantation that are suspected of PHV endocarditis.
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Figure 3. Attenuation-corrected 18F-FDG PET images (A, B) and fused images (C, D) of a patient
with a high level of myocardial 18F-FDG uptake making correct measurements of the SUV values
more difficult.
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